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BACKGROUND: Blood-based biomarkers may be particularly useful for patient selection and prediction of treatment response for
angiogenesis inhibitors. Circulating endothelial cells (CECs) and haematopoietic progenitor cells (HPCs) might have a role in tumour
angiogenesis and in tumour growth. Measurement of CECs and HPCs in the blood of patients could be a simple, non-invasive way to
monitor or predict responses to treatment.
METHODS: (VEGFR2
þ) CECs, (CD133
þ) HPCs, plasma vascular endothelial growth factor (VEGF) and erythropoietin were measured
in blood from 25 non-small cell lung cancer (NSCLC) patients before and during treatment with sorafenib plus erlotinib (SO/ER).
In order to assess the drug specificity of changes in CECs and HPCs, 18 patients treated with bevacizumab plus erlotinib (BV/ER) and
10 patients with erlotinib (ER) monotherapy were studied. Response was measured in all patient groups by Response Evaluation
Criteria in Solid Tumors (RECIST).
RESULTS: At day 7, SO/ER-treated patients showed a three-fold increase in CECs (Po0.0001) comparable to BV/ER-treated patients
(Po0.01), and the CECs did not change with erlotinib treatment (P¼0.8). At day 7, CD133
þ/HPCs decreased with SO/ER
treatment (Po0.0001). HPC numbers did not change with either BV/ER or erlotinib. In SO/ER-treated patients pre-treatment
CD133
þ/HPCs were significantly lower in responders (P¼0.01) and pre-treatment CD133
þ/HPC numbers lower than the median
correlated with a longer time-to-progression (TTP) (P¼0.037).
CONCLUSION: Pre-treatment CD133
þ/HPCs are a promising candidate biomarker to further explore for use in selecting NSCLC
patients who might benefit from SO/ER treatment.
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Anti-angiogenic agents used to target tumour neovascularization
can be classified into two groups: agents binding the vascular
endothelial growth factor (VEGF), such as the humanised mono-
clonal antibody (Mab) bevacizumab or the soluble decoy receptor
VEGF Trap and second, the receptor tyrosine kinase inhibitors
(TKIs) targeting the VEGF receptor family, such as sunitinib and
sorafenib.
Bevacizumab has proven efficacy against several solid tumours
(Presta et al, 1997), amongst others against non-small cell
lung cancer (NSCLC). A phase III study by Sandler et al (2006)
showed a survival benefit in advanced stage NSCLC patients
when bevacizumab was combined with chemotherapy in first-line
setting. This was recently confirmed by Manegold et al (2008).
Moreover, a phase I/II trial combining the epidermal growth factor
receptor (EGFR) inhibitor erlotinib or chemotherapy with
bevacizumab resulted in higher response rates and longer median
progression-free survival (PFS) in both bevacizumab containing
arms (Herbst et al, 2007).
The orally available anti-angiogenic TKI, sorafenib is a multi-
targeted inhibitor of raf-kinase, VEGFR1, VEGFR2, VEGFR3,
PDGFR-b, Flt3 and c-kit, which has been approved in the
treatment of both advanced renal cell carcinoma and hepato-
celullar carcinoma. There is an emerging evidence of clinical
anti-tumour activity in NSCLC (Gatzemeier et al, 2006; Schiller
et al, 2008).
Although anti-tumour activity is achieved by these anti-
angiogenic drugs either as monotherapy or in combination with
chemotherapy or with other targeted agents, it remains unclear
which patient will benefit most from treatment (Broxterman et al,
2009). Biomarkers that potentially predict treatment response, in
order to guide patient selection and/or monitor early response, are
currently being investigated (Le Tourneau et al, 2008; Pathak et al,
2008).
Particularly attractive biomarkers might be circulating endo-
thelial cells (CECs), as these may reflect damage to the tumour
vasculature or circulating haematopoietic progenitor cells (HPCs),
as they have been proposed to reflect a pro-angiogenic cell
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spopulation, which may respond to increased hypoxia by effective
anti-angiogenic therapy (Jain and Duda, 2003; Shaked et al, 2006;
Zurita et al, 2009).
No studies are currently available assessing the effects of anti-
angiogenic agents in NSCLC patients on CECs and HPCs. In this
study we evaluated (1) changes in CECs, defined as CD34
bright/
CD45
 /(VEGFR2
þ), and HPCs, defined as CD34
bright/CD45
dim/
(CD133
þ), in NSCLC patients treated with anti-angiogenic therapy
with sorafenib plus erlotinib (SO/ER); (2) we investigated the
specificity of these changes by comparing these with a control
group of patients receiving bevacizumab plus erlotinib (BV/ER) or
monotherapy erlotinib, and (3) we correlated the changes of the
biomarkers with treatment response in the SO/ER patient group.
MATERIALS AND METHODS
Patient and study design
From November 2007 to October 2008 25 chemotherapy-naive
patients with advanced NSCLC who were treated at the VU
University Medical Center in a phase II trial combining erlotinib
(150mgday
 1) and sorafenib (400mg twice daily) were enrolled in
this study (Lind et al, 2009a).
For comparison, a cohort of 18 NSCLC patients treated with
bevacizumab (15mgkg
 1 intravenously every 21 days) plus
erlotinib (150mgday
 1 orally) in a phase II trial (Groen et al,
2007) and a control group of 10 patients treated with whole brain
radiotherapy (WBRT) plus concurrent erlotinib for brain meta-
stases from NSCLC in phase I trial were evaluated (Lind et al,
2009b). These control group patients received erlotinib 1 week
before and during WBRT (30Gy in 10 once-daily fractions) and
continued maintenance erlotinib (150mgday
 1) until unaccept-
able toxicity or disease progression.
Before study entry, all patients provided written informed
consent in accordance with the national and institutional guide-
lines, which strictly adhere to the principles of the Declaration of
Helsinki and ICH/Good Clinical Practice.
Peripheral blood (PB) was taken from all patients on three
occasions: before start of treatment, day (D) 0, and 7 and 21 days
after starting drug treatment, D7 and D21, respectively. Computed
tomography was carried out before and 6 weeks after the start of
treatment to assess clinical response according to the Response
Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al,
2000). In the SO/ER-treated patients response incorporating
primary tumour cavitations, as proposed by Crabb et al (2009),
were also determined. Clinical responses after 6 weeks of treat-
ment were used to examine a possible relation with VEGF and
erythropoietin (EPO, in SO/ER-treated patients only) levels and the
cellular biomarkers.
Evaluation of cells and plasma biomarkers
Blood from SO/ER-treated patients was collected in EDTA tubes
and the circulating HPCs and CECs were measured using a full-
blood flow cytometric method as previously described (Vroling
et al, 2007, 2009). (CD133
þ) HPCs were defined as CD34
bright/
CD45
dim (and CD133
þ) and CECs were defined as CD34
bright/
CD45
neg and largely positive for VEGFR2. The antibodies used
to carry out analysis in this study included CD45–FITC, CD34–
APC, CD133–PE, VEGFR2–PE and viability marker 7-AAD. Cell
populations were measured by flow cytometry (FACSCalibur, BD
Bioscience, Breda, The Netherlands) in a total volume of 1.5ml
full blood and appropriate IgG isotypes were used as a control.
Circulating cells from the comparison groups (monotherapy
erlotinib and BV/ER) were assessed with CD45–FITC, CD34–
APC and 7-AAD. Cell populations of the total white blood cells
(WBC) were calculated as numberml
 1 of blood using blood cell
count measured on a Sysmex. EDTA blood was used for the collection
of plasma, which was stored at  801C until further analysis. Plasma
VEGF and EPO levels were measured in duplicate with the enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis,
MN, USA).
Statistical analyses
Circulating cell populations (numbersml
 1), plasma levels of
VEGF (pgml
 1) and EPO (mIUml
 1) were expressed as median
(range). Continuous variables between groups were compared with
Mann–Whitney U-test. To compare the blood-based parameters at
pre-treatment with those during treatment (D0, D7 and D21) the
Wilcoxon’s signed-rank test was used. Time-to-progression (TTP)
was determined as the time period from start of treatment to the
time of documented disease progression with a minimum follow-
up period of 6 months. Overall survival (OS) was the time between
the first day of treatment and the date of death or the date on
which patients were last known to be alive. Correlations of the
circulating cells with TTP and overall OS were determined with
the Kaplan–Meier method and its associated log-rank statistic.
Responders were defined as those achieving partial response
(PR) according to RECIST and non-responders as those with
stable disease (SD) or progressive disease (PD) after 6 weeks of
treatment. Differences were considered statistically significant
when Po0.05 (two-tailed). As this was an exploratory study, no
correction for multiple testing was done. Statistical analyses were
carried out with SPSS (SPSS for Windows 15.0, SPSS, Chicago, IL,
USA) software programme.
RESULTS
Patient characteristics and treatment response
In total, 53 NSCLC patients in three study groups were investi-
gated. Patients treated with SO/ER included in this study (14 males
and 11 females) had a median age of 60 years (range 41–78) at the
start of treatment. The clinical response of patients was assessed
using RECIST criteria (Therasse et al, 2000). Thirteen out of
the 25 SO/ER-treated patients had developed cavitations in the
primary tumour at week 6 of evaluation. For these patients,
responses incorporating cavitations were also correlated with the
circulating cells and plasma parameters. Patients treated with
SO/ER had a median TTP of 6 months (range 0.82–12.7) and an
OS of 12.4 months (range 2.3–16.0). Patients treated with BV/ER
had a median TTP of 6.8 months (range 3.2–10.3) and an OS of
6.9 months (range 5.4–8.3). Further, patient and tumour charac-
teristics are summarised in Table 1.
Definitions of HPCs and CECs populations
The FACS analysis of a blood sample of a representative patient
from the study is shown in Figure 1. As described previously for
renal cell cancer patients (Vroling et al, 2009), two distinct CD34
þ
cell populations, which differ in the expression of the leucocyte
marker CD45 and progenitor marker CD133, were identified in
NSCLC patients. HPCs are the CD45
dim/CD34
bright cells, which are
largely CD133
pos. The cutoff value for CD133 positivity in HPCs
was determined based on isotype control and was adjusted for
every individual sample. CECs are CD34
bright, which are almost
uniformly positive for VEGFR2, but lack both markers CD45 and
CD133 as previously defined (Vroling et al, 2007, 2009) (Figure 1).
Marked decrease of HPCs during treatment with TKI
sorafenib
The total WBC count showed little change during treatment with
SO/ER, BV/ER or monotherapy erlotinib (Figure 2A). Although no
CECs and HPCs in NSCLC patients
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we found a marked decrease of HPCs (Figure 2B) after 7 days
of treatment with SO/ER (median from 1345cellsml
 1 at D0
to 511cellsml
 1 on D7, Po0.001), which decreased further after
3 weeks of treatment (to a median of 356cellsml
 1, Po0.0001).
The sub-population of CD133
þ/HPCs also showed a similar
decrease (from 1086cellsml
 1 at D0 to 361cellsml
 1 on D7
(Po0.0001) to 264cellsml
 1 on D21 (Po0.0001)). In the patient
groups, treated with either BV/ER or monotherapy erlotinib, the
HPC numbers did not change significantly (Figure 2B).
Anti-angiogenic treatment-specific increase of CECs
Patients treated with SO/ER showed an increase in the number of
CECs, which was also found in patients treated with BV/ER but not
with monotherapy erlotinib (Figure 2C). SO/ER-treated patients
showed a three-fold increase in CECs on D7 (median, from 41 to
124cellsml
 1, P¼0.001) and BV/ER-treated patients more than
a two-fold increase in CECs (median, from 59 to 132cellsml
 1,
P¼0.002). CECs during monotherapy erlotinib did not change
after 7 days of treatment (median, from 48 to 51cellsml
 1,
P¼0.8). The VEGFR2 positive fraction of CECs enumerated in
SO/ER-treated patients followed the same trend as total CECs
(Figure 2D). In both patient groups treated with either a TKI
or anti-VEGF, Mab-angiogenesis inhibitor CECs further increased
after 3 weeks of treatment in contrast to patients treated with
monotherapy erlotinib (Figure 3).
Response and biomarkers
In order to analyse the possible relations of biomarker values with
response we used RECIST criteria and RECIST criteria taking into
account tumour cavitations as recently suggested by Crabb et al
(2009). CD133
þ/HPCs were not significantly correlated with the
response when RECIST was not adjusted for tumour cavitations.
When the response was corrected for cavitations, pre-treatment
levels of CD133
þ/HPCs but not the total HPCs, were significantly
lower in responding (PR) patients compared with non-responding
(SDþPD) patients treated with SO/ER (P¼0.01 and P¼0.28
respectively, Figure 4A). Nine out of 12 patients with lower than
the median of 1086 CD133
þ/HPCsml
 1 and 4 out 12 with higher
than the median of CD133
þ/HPCs showed a response (PR).
Patients with low CD133
þ/HPCs (lower than the median of
1086cellsml
 1) had a significantly longer TTP than those with
CD133
þ/HPCs higher than the median pre-treatment levels, which
was again not seen for the total population of HPCs (Po0.05 and
P¼0.334 respectively, Figure 4B). TTP was calculated from
RECIST not corrected for tumour cavitations, as this is currently
not validated. At the time of analyses CD133
þ/HPCs did not
correlate with OS. Pre-treatment CECs or changes in CECs after
7 or 21 days in patients treated with SO/ER did not correlate
with TTP, OS or response (according RECIST) with or without
adjustments for cavitations. The latter was comparable for patients
treated with BV/ER.
Plasma VEGF and EPO levels in NSCLC patients
Patients treated with SO/ER showed a slight non-significant increase
in plasma VEGF during 21 days of treatment (Figure 5A), which
was similar in patients treated with monotherapy erlotinib (data
not shown). BV/ER-treated patients showed a significant decrease
in plasma VEGF levels after 7 days (median decreased from 134
to 25pgml
 1, P¼0.002, data not shown), probably because the
used ELISA-kit measures only free VEGF (Loupakis et al, 2007).
No correlation was found between pre-treatment plasma VEGF
levels and treatment outcome. Moreover, we found no significant
relationship between the (VEGFR2
þ) CECs, (CD133
þ) HPCs
and pre-treatment plasma VEGF in any patient group (data
not shown).
To investigate if plasma EPO levels can serve as a surrogate
pharmacodynamic biomarker or may have a possible relation
with CECs and HPCs the plasma EPO levels were determined in
the SO/ER-treated patients. Minor changes in plasma EPO were
observed (median, from 6.5 on D0 to 6.6 on D7 to 7.8mIUml
 1 on
D21, Figure 5B) which were all in the normal range of EPO levels
(3.1–14.9mIUml
 1). Pre-treatment plasma EPO levels showed no
correlation with circulating cell numbers or patient response (data
not shown).
DISCUSSION
We monitored, to our knowledge for the first time, VEGFR2-positive
circulating endothelial cells and CD133-positive haematopoietic
Table 1 Patient characteristics and response to treatment at 6 weeks
Characteristic SO/ER BV/ER ER
N (%) N (%) N (%)
Total 25 18 10
Sex
Male 14 (44) 12 (67) 4 (40)
Female 11 (56) 6 (33) 6 (60)
Median age (years) (range) 60 (41–78) 63 (34–80) 68 (59–77)
Smoking status
Current or former smoker 20 (80) 18 (100) 9 (90)
Non-smoker 5 (20) 0 1 (10)
ECOG performance status
0 17 (68) 5 (28) 2 (20)
1 8 (32) 9 (50) 7 (70)
2 0 4 (22) 1 (10)
Tumour histology
Adenocarcinoma 18 (72) 12 (67) 5 (50)
Large cell 2 (8) 5 (28) 4 (40)
Squamous cell 1 (4) 0 1 (10)
BAC 2 (8) 1 (6) 0
NSCLC NOS 2 (8) 0 0
Tumour stage
IIIB 7 (28) 5 (28) 1 (10)
IV 18 (72) 13 (72) 9 (90)
Previous treatment
Yes 2 (8) 0 5 (50)
No 23 (92) 18 (100) 5 (50)
Response at 6 weeks
Partial response 10 (40) 4 (22) 0
Stable disease 12 (48) 10 (56) 8 (80)
Progressive disease 3 (12)
a 4 (22) 2 (20)
Response at 6 weeks corrected for cavitations ——
Partial response 13 (52)
Stable disease 9 (36)
Progressive disease 2 (8)
a
Median time to progression,
months (95% CI)
6.0 (11.7–13.2) 6.8 (3.2–10.3) 6.6 (2.6–10.7)
Median survival,
months (95% CI)
12.5 (11.7–13.2) 6.9 (5.4–8.3) 6.0 (0–12.8)
Abbreviations: BAC¼bronchioloalveolar carcinoma; BV¼bevacizumab; ECOG¼
Eastern Cooperative Oncology Group; ER¼erlotinib; SO¼sorafenib.
aOne PD
patient had no formal evaluation for treatment response because of early off study
due to treatment-related toxicity.
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agent SO combined with ER. The second objective of the study was
to provide data on the specificity of the measured changes in CECs
and HPCs for SO/ER treatment. For this purpose data from two
smaller groups of patients were obtained. The most important
findings we report here are:
(1) VEGFR2
þ CECs increase in an anti-VEGF treatment-specific
manner, with a similar two- to three-fold increase (on D7 or
D21) after treatment with the VEGFR–TKI sorafenib or anti-
VEGF antibody bevacizumab, both combined with the EGFR–
TKI erlotinib, but not with erlotinib monotherapy (see
Figure 2C).
(2) CD133
þ/HPCs markedly decreased with 460% on D7 and
about 75% on D21 of treatment with SO/ER. This effect is not
seen during treatment with BV/ER or monotherapy erlotinib
with whole brain radiotherapy.
(3) The pre-treatment CD133
þ/HPC numbers predicted for
response incorporating tumour cavitations to SO/ER therapy.
In addition, TTP defined by RECIST was significantly longer
in the patient group with a lower than median number of
CD133
þ HPCs.
Circulating endothelial cells are a very rare cell population,
normally defined as mature endothelial cells shed from the
vasculature and are considered to be a useful biomarker of
vascular damage (Willett et al, 2004; Duda et al, 2006; Batchelor
et al, 2007; Norden-Zfoni et al, 2007). In addition, the possibility to
monitor circulating endothelial progenitor cells (CEPs) has been
proposed as an attractive biomarker for anti-angiogenic agents
after the seminal identification of circulating progenitors, which
could grow out to highly proliferative endothelial outgrowth
cells (EOCs) (Ingram et al, 2005; Shaked et al, 2006). Although
originally CEPs were discriminated from mature CECs mainly by
the presence or absence of CD133 progenitor markers, more recent
data have cast serious doubts on this premise (Timmermans et al,
2008; Yoder and Ingram, 2009).
The population of CECs that we have monitored has a
phenotype consistent with a population containing the precursor
for EOCs, namely CD34
þ, VEGFR2
þ, but CD45
  and CD133
  (see
Figure 1) according to Case et al (2007) and Timmermans et al
(2007). However, whether CECs are a mixed mature/progenitor
population will only be determined once these very rare cells can
be sorted after a unique specific marker of the endothelial
progenitor cell will have been identified (Yoder and Ingram, 2009).
In this study, the CEC population did not predict for response to
SO/ER or BV/ER therapy. Regarding the explanations for the lack
of correlation between pre-treatment values or increases in CECs
and response one can only speculate. Our finding of an increase in
CECs in SO/ER or BV/ER, but not monotherapy erlotinib-treated
patients is consistent with our earlier finding of a similar increase
in renal cell cancer patients treated with the VEGFR–TKI sunitinib
(Vroling et al, 2009). Therefore, the increase of this cell population
is likely to be a pharmacodynamic marker for VEGF/VEGFR
signalling-inhibitor therapy.
Preclinical and early clinical data (phase I and phase II trials)
have supported combined inhibition of VEGFR and EGFR
pathways in NSCLC (Pennell and Lynch, 2009). Activating EGFR
mutations are predictive of response to EGFR inhibitors with
reported response rates of upto 75%. In the specific group
studied here, six out of eight (75%) patients with an activating
EGFR mutation showed a response (PR). Of the WT EGFR group 6
out of 13 (46%) patients showed a response (PR). This is higher
than the rates reported for erlotinib monotherapy and implies a
significant contribution of sorafenib on the clinical outcome with
this combination treatment. The currently identified CD133
þ
progenitor cell population might be of help in future evaluation
of this type of combination therapy.
Unlike CECs, the total HPC population showed a marked
decrease during SO/ER treatment in contrast to patients treated
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Figure 1 Full blood analysis of circulating endothelial cells (CECs) and haematopoietic progenitor cells (HPCs) in a non-small cell lung cancer (NSCLC)
patient. (A) Detection of total CECs and HPCs based on marker expression of CD45 and CD34. CECs by CD45
neg/CD34
bright and HPCs defined by
CD45
dim/CD34
bright.( B) Expression of VEGFR2 and CD133 on CECs and HPCs as indicated by the boxes.
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swith BV/ER or monotherapy erlotinib with WBRT. Such a decrease
of the HPCs also occurs in RCC patients treated with sunitinib
(Vroling et al, 2009) and might be related to the Flt-3 inhibitory
effects of both TKI sorafenib and sunitinib, as Flt3-signalling is
required for HPC proliferation and mobilisation into the circula-
tion (Gabbianelli et al, 1995; Faivre et al, 2007; Kumar et al, 2009).
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sIn this study, the pre-treatment level of the CD133
þ/HPCs
was significantly higher in the non-responders to SO/ER therapy,
and the group with higher than median CD133
þ/HPC values
showed a shorter TTP. Also, the decrease in CD133
þ/HPCs on
D7 was much smaller in patients with longer TTP (data not
shown), which may be a reflection of the lower HPC mobilisation
from the bone marrow into the circulation in those patients.
Although the inhibition of circulating HPC numbers is very likely
a pharmacological effect of sorafenib, the correlation with the anti-
tumour effect (of the sorafenib plus erlotinib combination) may or
may not be indicative of a role of this population in tumour
growth. In contrast to the hypothesised effects of populations of
circulating endothelial progenitors, a pro-angiogenic role of HPCs
and CD133
þ sub-populations of HPCs recruited from the bone
marrow to hypoxic or tumour tissues (Kerbel, 2008; Burt et al,
2009) is consistently reported. Thus, there is wide agreement on
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Figure 4 Boxplots and Kaplan–Meier curves, according to peripheral blood circulating CD133
þ/haematopoietic progenitor cells (HPCs) in sorafenib plus
erlotinib (SO/ER)-treated non-small cell lung cancer (NSCLC) patients. (A) Mean pre-treatment numbers of CD133
þ/HPC of non-responders (n¼11)
and responders (n¼13). Responses are according to Response Evaluation Criteria in Solid Tumors (RECIST) incorporated cavitations. *¼Po0.05.
(B) Time-to-progression (TTP) according to RECIST correlated with pre-treatment CD133
þ/HPCs and the total population of HPCs with a median cutoff
value of 1086 and 1345cellsml
 1, respectively. ‘Low’ indicates (CD133
þ)/HPCs at baseline below the median and ‘high’ indicates (CD133
þ)/HPCs at
baseline higher than the median.
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Figure 5 Plasma vascular endothelial growth factor (VEGF) and erythropoietin (EPO) levels in non-small cell lung cancer (NSCLC) patients treated
with SO/ER. (A) Free plasma VEGF levels (pgml
 1) did not change significantly during 21 days of sorafenib plus erlotinib (SO/ER) (n¼25). *Po0.01.
(B) Plasma EPO levels (mIUml
 1) in NSCLC patients showed a slight increase during sorafenib treatment. (D21, *Po0.01).
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adult neovascularization. The ongoing debate is on the evidence
for the existence in the adult of bone marrow-derived progenitors
for potent long-term endothelial layer forming cells in addition to
the progenitors for cell populations that promote tumour
neovascularization indirectly by secreting growth factors. How-
ever, present studies point to a limited incorporation of bone
marrow-derived cells into the endothelium of tumours (Peters
et al, 2005). Many recent studies and reviews discuss the properties
of pro-angiogenic cell populations or ‘circulating angiogenic cells’
in depth (Case et al, 2007; Timmermans et al, 2007, 2008; Hirschi
et al, 2008; Gao et al, 2009; Yoder and Ingram, 2009).
A specific role of CD133
þ/HPCs has been suggested in
pulmonary vascular remodelling in patients with obstructive
pulmonary disease (Asosingh et al, 2008) or idiopathic pulmonary
arterial hypertension (Diez et al, 2007). Thus, it seems plausible
that the production and release of cytokines, chemokines and
proteolytic enzymes (VEGF, SDF-1 and metalloproteases) by the
lung tumour tissue will increase the mobilisation of CD133
þ/HPCs
from the bone marrow, which may be home to hypoxic tumour
tissue and have a fundamental role in tumour neovascularization
and progression (Kerbel, 2008; Shojaei and Ferrara, 2008).
In this scenario, part of the anti-tumour effect of sorafenib, but
also sunitinib, may be related to the suppression of mobilisation of
(CD133
þ) HPCs from the bone marrow. Other studies also suggest
that high numbers of circulating CD133
þ/HPCs are related to a
worse outcome in cancer patients. CD133 mRNA from PB cells,
which is predominantly derived from the HPCs was shown to be an
independent prognostic factor for patient survival (Mehra et al,
2006).
A very recent study showed that higher pre-treatment levels of
CD133
þ/CD34
þ/CD45
dim cells (called circulating progenitor cells
in that study) were associated with the worst outcome of suntinib
therapy in hepatocellular carcinoma (Zhu et al, 2009).
Altogether, these results fit with the concept of the pro-
angiogenic capacity of HPCs in tumour neovascularization and
might indicate a causative role of the suppression of these cells by
the anti-angiogenic TKIs sorafenib and/or sunitinb to their anti-
tumour effects and patient responses. As this cell population is well
defined, it is also amenable to analysis at the RNA level in PB
mononuclear cells.
In addition, plasma levels of VEGF and EPO (representing a
larger repertoire of cytokines/growth factors) are known to be
increased in mice or patients upon treatment with anti-VEGF
therapy (Ebos et al, 2007; Vroling et al, 2009) and have early on
been considered as candidate biomarkers for the effectivity of this
type of therapy. In this study, VEGF and EPO, were not predictive
of response or TTP to SO/ER-combination therapy. Dowlati et al
(2008) found that VEGF was predictive for response in NSCLC
patients treated with bevacizumab, but no relation was found with
survival.
An important difficulty in defining or identifying biomarkers is
the evaluation of the endpoint of the actual responses of the
patients. RECIST is the most widely used method for assessing
the responses of patients (Therasse et al, 2000), but has been
critically updated by Karrison et al (2007) and Verweij et al (2009).
In addition Crabb et al (2009) suggest that response assessment
might be improved in NSCLC patients, treated with angiogenesis
inhibitors, by incorporating cavitation into volume assessment for
target lesions potentially altering treatment outcomes. In that
study, marked pulmonary cavitation occurred in 24% of patients
treated with the angiogenesis inhibitor cediranib plus chemo-
therapy, which was not seen with chemotherapy alone. Our
sorafenib data suggest that correcting for cavitations may be of
importance in evaluating potential biomarkers in relation to
response. In SO/ER-treated patients 13 out of 25 patients had
cavitations because of the treatment. Incorporating these cavita-
tions in response assessment altered the RECIST responses. Pre-
treatment numbers of CD133
þ/HPCs were only prognostic for the
response if corrected for cavitations.
In our study, several cell populations and plasma markers were
evaluated to serve as a potential biomarker during anti-angiogen-
esis treatment. This introduces the potential problem of multiple
testing, which increases the risk to find false-positive relations.
Clearly, our study was designed to explore associations that should
be confirmed in an independent group of patients.
In conclusion, CECs increased in NSCLC patients treated with
SO/ER and BV/ER, but not with erlotinib monotherapy. Thus, this
effect can be ascribed to the anti-angiogenic agents. The CD133
þ/
HPCs decreased significantly in all patients treated with SO/ER and
pre-treatment numbers were significantly lower in responding
patients and pre-treatment CD133
þ/HPC numbers correlated with
the TTP. CD133
þ/HPCs may therefore be considered for further
investigations as a biomarker for selecting patients who are likely
to benefit from SO/ER.
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